A study reported by News-Medical describes an experimental drug delivery method that uses particles made with RNA molecules to transport chemotherapy and potentially other treatments directly to tumours in mice.
The approach relies on “micelles,” which are very small, particle-like structures that can be engineered to carry therapeutic payloads. In this work, the micelles were built using RNA, a biological molecule better known for its role in translating genetic information into proteins.
According to the report, the RNA micelles were designed to concentrate chemotherapy at tumour sites. The aim is to improve how much of a cancer drug reaches the intended target while reducing exposure in healthy tissues.
In the mouse experiments described, delivering chemotherapy with these RNA micelles led to tumour cell death. The report also notes that the treatment did not trigger an immune response and did not produce side effects linked to toxicity in the animals studied.
A key challenge for many cancer therapies is balancing effectiveness with tolerability. Chemotherapy drugs can harm fast-growing healthy cells as well as cancer cells, which contributes to adverse effects. Another challenge in advanced drug delivery systems is that some carriers can provoke inflammation or immune activation, potentially limiting repeated dosing.
The findings highlighted in the report suggest the RNA micelles may help address both problems: they may enable more targeted delivery to tumours while avoiding immune-related complications and toxicity-associated side effects in the tested mice.
The work is described as a preclinical study, meaning the results come from animal models rather than human trials. Further research would be required to confirm how the approach performs in additional studies and whether it can be adapted safely and effectively for use in people.
Beyond chemotherapy, the report indicates the same delivery platform could be explored for transporting other types of therapies to tumours, potentially widening its applications in cancer treatment research.